Why is Pfizer falling/rising?

As of 31-Jul, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,228.40, which reflects a decrease of 22.6 points or 0.43%. The stock has been underperforming recently, with a consecutive fall over the last two days resulting in a total drop of 0.99%. In the past week, it has decreased by 0.51%, and over the past month, it has seen a significant decline of 8.11%. Despite this, the stock has outperformed its sector by 1.06% today. Key financial metrics indicate high management efficiency with a return on equity of 19.67% and a low debt-to-equity ratio, which may provide some support to the stock's fundamentals. However, falling investor participation, as evidenced by a 19.03% drop in delivery volume, could be contributing to the stock's recent downward trend.
In the broader market context, Pfizer's short-term performance has been better than the benchmark Sensex, which has declined by 1.22% over the past week. However, the stock has underperformed the Sensex over the longer term, with a year-to-date return of -0.49% compared to the Sensex's positive return of 3.90%. This suggests that while Pfizer is facing challenges, it is not alone in its struggles, as the overall market has also seen declines. The high dividend yield of 3.81% may attract some investors, but the overall sentiment appears to be cautious given the recent price movements and declining trading volumes.